Voyageur Pharmaceuticals Appoints Financial Expert Virginia Alling to Board to Accelerate U.S. Market Expansion

Voyageur Pharmaceuticals Ltd. has announced the appointment of Virginia Alling as an independent director, subject to regulatory approval, marking the company's latest strategic move to enhance its board with Wall Street veterans. This appointment follows recent additions of Jeffrey J. Kraws and Christopher A. Van Buren, collectively positioning the Canadian pharmaceutical developer for accelerated U.S. capital market access and strategic growth initiatives.

Alling brings over three decades of experience in corporate banking, capital markets, and strategic advisory services for both privately held and publicly traded companies. As Senior Vice President & Managing Director at PNC Bank in East Brunswick, NJ, she manages a multi-billion-dollar portfolio of corporate clients across New Jersey and New York, with expertise spanning mergers and acquisitions, initial public offerings, employee stock ownership plans, leveraged finance, and revenue optimization. Her background includes guiding private equity-backed and multigenerational family-owned businesses through capital structure solutions, succession planning, and risk management strategies.

Prior to her role at PNC Bank, Alling served as Vice President in Corporate Finance & Corporate Banking at JPMorgan Chase (formerly Chemical Bank) in New Jersey and Assistant Vice President at Wells Fargo (formerly CoreStates) in Philadelphia. She holds an MBA from the Raymond A. Mason School of Business at the College of William & Mary and maintains FINRA Series 7 & 63 licenses as a Registered Investment Adviser. Beyond her corporate responsibilities, Alling maintains active involvement in board leadership and nonprofit work, with particular focus on advancing technology, healthcare, and philanthropic initiatives.

Brent Willis, Voyageur's CEO, emphasized the strategic importance of Alling's appointment, noting that her track record in executing U.S. public offerings, revenue optimization, and cross-border financing complements the recent board enhancements. Willis stated that Alling's deep experience in mergers and acquisitions and capital markets will be instrumental in unlocking institutional U.S. investment, streamlining the company's U.S. market entry, and ensuring robust governance as Voyageur scales its innovative barium and iodine pipeline for North American healthcare providers.

The collective expertise of Alling, Kraws, and Van Buren underscores Voyageur's commitment to assembling a high-caliber board with proven Wall Street acumen to facilitate U.S. market expansion. Their combined experience in revenue generation, IPO execution, and regulatory compliance is expected to support Voyageur's commercialization efforts, including securing FDA approvals for its barium contrast products and scaling its Oklahoma iodine operations. This strategic board enhancement comes at a critical juncture as Voyageur pursues its vision of becoming the first vertically integrated company in the radiology contrast media drug market, controlling all primary input costs from raw material sourcing to final production under its "From the Earth to the Bottle" philosophy.

Voyageur's business model focuses on developing pharmaceutical-grade barium and iodine Active Pharmaceutical Ingredients for medical imaging contrast media, with plans to generate sales through partnerships with established third-party GMP pharmaceutical manufacturers in Canada. The company owns 100% interest in the Frances Creek barium sulphate project, which features a rare mineral grade suitable for pharmaceutical applications that the company believes will replace current synthetic products with higher quality imaging alternatives. Additional information about the company's operations and strategic direction can be found at https://voyageurpharmaceuticals.ca.